A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))
Arms / Cohorts
Experimental:Newly Diagnosed: Idarubicin + Cladribine + Cytarabine + Quizartinib
Accepting patients
Experimental:Relapsed or Refractory: Idarubicin + Cladribine + Cytarabine + Quizartinib
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.